OVERALL SURVIVAL IN POST-MENOPAUSAL WOMEN WITH HR+/HER2-ADVANCED BREAST CANCER RECEIVING A CDK 4 AND 6 INHIBITOR plus FULVESTRANT AFTER PROGRESSING ON/AFTER PRIOR ENDOCRINE THERAPY: A FRACTIONAL POLYNOMIAL NETWORK META-ANALYSIS

被引：0
|
作者：
Hirst, A. [1 ]
Davie, A. [2 ]
Carter, Cuyun G. [3 ]
Haddad, N. [3 ]
Traore, S. [2 ]
Brufsky, A. [4 ]
Harbeck, N. [5 ]
Pivot, X. [6 ]
机构：
[1] ICON PLC, London, England
[2] Eli Lilly & Co Ltd, Windlesham, Surrey, England
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
[4] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[5] Univ Munchen LMU, Brustzentrum, Munich, Germany
[6] Paul Strauss Canc Ctr, Strasbourg, France
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN4
引用
收藏
页码：S421 / S421
页数：1
相关论文
共 50 条
  • [41] FGFR1 and RB1 genetic alteration impair clinical benefit of CDK4/6 inhibitors plus endocrine therapy in HR+/HER2-advanced breast cancer
    Zhong, Jianxin
    Shao, Bin
    Jiang, Hanfang
    Li, Huiping
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [42] MONARCH 2: subgroup analysis of patients receiving abema-ciclib plus fulvestrant as first- and second-line therapy for HR+, HER2-advanced breast cancer (ABC)
    Neven, P.
    Johnston, S.
    Toi, M.
    Sohn, J.
    Inoue, K.
    Pivot, X.
    Burdaeva, O.
    Okera, M.
    Masuda, N.
    Koh, H.
    Grischke, E. -M.
    Conte, P.
    Lu, Y.
    Haddad, N.
    Hurt, K.
    Kaufman, P. A.
    Llombart Cussac, A.
    Sledge, G. W., Jr.
    Bodmer, A.
    SWISS MEDICAL WEEKLY, 2020, : 8S - 8S
  • [43] The effect and safety of CDK4/6 inhibitors combined endocrine therapy on HR+, HER2-breast cancer: a meta-analysis of randomized controlled trials
    Huang, Tongmin
    He, Yujing
    Yu, Chiyuan
    Mao, Feiyan
    Si, Yuexiu
    ENDOKRYNOLOGIA POLSKA, 2023, 74 (01) : 89 - 105
  • [44] Comparative effectiveness of palbociclib plus aromatase inhibitor versus fulvestrant alone as initial endocrine therapy for HR+/HER2-advanced breast cancer in Chinese clinical practice: A real-world study
    Yue, Jian
    Yuan, Peng
    Wang, Xue
    Ju, Jie
    Gao, Song-lin
    Yang, Zixuan
    Kang, Yikun
    Lei, Zixuan
    Shuai, You
    Wei, Tong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] Comparative effectiveness of Palbociclib plus Aromatase inhibitor versus fulvestrant alone as initial endocrine therapy for HR+/HER2-advanced breast cancer in Chinese clinical practice: a real-world study
    Yue, Jian
    Wang, Xue
    Ju, Jie
    Yang, Zixiang
    Wei, Tong
    Yuan, Peng
    Gao, Min
    Xu, Ling
    Guan, Yin
    CANCER RESEARCH, 2024, 84 (09)
  • [46] A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2-advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1)
    Hurvitz, Sara
    Andre, Fabrice
    Cristofanilli, Massimo
    Curigliano, Giuseppe
    Giordano, Antonio
    Han, Hyo
    Martin, Miguel
    Pistilli, Barbara
    Rugo, Hope
    Wesolowski, Robert
    Gorbatchevsky, Igor
    Loibl, Sibylle
    CANCER RESEARCH, 2024, 84 (09)
  • [47] A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2-advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1)
    Hurvitz, Sara
    Andre, Fabrice
    Cristofanilli, Massimo
    Curigliano, Giuseppe
    Giordano, Antonio
    Han, Hyo S.
    Martin, Miguel
    Pistilli, Barbara
    Rugo, Hope
    Wesolowski, Robert
    Suzuki, Samuel
    Mutka, Sarah C.
    Gorbatchevsky, Igor
    Loibl, Sibylle
    CANCER RESEARCH, 2023, 83 (05)
  • [48] Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant
    P. Neven
    P. A. Fasching
    S. Chia
    G. Jerusalem
    M. De Laurentiis
    S.-A. Im
    K. Petrakova
    G. V. Bianchi
    M. Martín
    A. Nusch
    G. S. Sonke
    L. De la Cruz-Merino
    J. T. Beck
    J. P. Zarate
    Y. Wang
    A. Chakravartty
    C. Wang
    D. J. Slamon
    Breast Cancer Research, 25
  • [49] Comparative efficacy and safety of CDK4/6 inhibitors combined with endocrine therapies for HR+/HER2-breast cancer: Systematic review and network meta-analysis
    Tong, Fei
    Lu, Yi
    Ma, Hong-Fang
    Shen, Jun
    HELIYON, 2024, 10 (11)
  • [50] Phase 2 study of palbociclib (CDK 4/6 inhibitor) for ER positive, HER2-negative post-menopausal advanced breast cancer patients recurring after hormonal therapy (to reverse endocrine resistance - TREnd trial)
    Malorni, L.
    Sanna, G.
    Pestrin, M.
    Siclari, O.
    Biganzoli, L.
    Biagioni, C.
    Cappadona, S.
    Migliaccio, I.
    Guarducci, C.
    Boni, L.
    Baldari, D.
    Minisini, A. M.
    Curigliano, G.
    Koehler, M.
    Buyse, M.
    Di Leo, A.
    CANCER RESEARCH, 2013, 73
12345